Amsterdam UMC, Vrije Universiteit Amsterdam, Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology and Metabolism, de Boelelaan 1117, Amsterdam, the Netherlands.
Amsterdam UMC, Vrije Universiteit Amsterdam, Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology and Metabolism, de Boelelaan 1117, Amsterdam, the Netherlands; Department of Gastroenterology and Hepatology, Radboudumc, Nijmegen, the Netherlands.
Eur J Intern Med. 2021 Aug;90:30-36. doi: 10.1016/j.ejim.2021.03.024. Epub 2021 Apr 14.
Recommendations for drug withdrawal in patients with autoimmune hepatitis (AIH) in longstanding remission are conflicting and rely on retrospective data. We prospectively investigated the predictive value of histological normalisation for successful treatment withdrawal in AIH patients.
Non-cirrhotic patients with established AIH and complete biochemical remission (normalisation of serum alanine aminotransferase [ALT] or aspartate aminotransferase [AST] and immunoglobulin G [IgG]) of at least 2 years were biopsied. Immunosuppressive therapy was only withdrawn in patients with histological normalisation (histological activity index [HAI] ≤3) with a minimum follow-up of 12 months.
A total of 17 patients in biochemical remission for at least 2 years were included. Persistent histological inflammatory activity (HAI >3) precluded drug withdrawal in five patients. These had higher values of ALT (25 vs. 16 U/L; p = 0.01) and AST (26 vs. 22 U/L; p = 0.01) compared with patients in histological remission. Immunosuppressive medication was withdrawn in 12 patients; eight (67%, C.I. 40-93% p = 0.4) remained in remission during a median follow-up of 62 months (range: 13-75 months); and four (33%, C.I. 7-60% p = 0.4) required reinstitution of therapy after 1, 6, 11, and 40 months, all without clinical signs of disease progression or hepatic decompensation. No predictors of relapse were identified.
Two-thirds of the patients who prove to have histological normalisation after at least 2 years of biochemical remission achieve treatment-free remission. Although patient numbers were small and results should be interpreted with caution, these findings support a liver biopsy prior to drug withdrawal.
对于长期缓解的自身免疫性肝炎(AIH)患者停药的建议存在争议,并且依赖于回顾性数据。我们前瞻性地研究了组织学正常化对 AIH 患者成功停药的预测价值。
对已确诊的 AIH 且至少 2 年生化缓解(血清丙氨酸氨基转移酶[ALT]或天冬氨酸氨基转移酶[AST]和免疫球蛋白 G[IgG]正常化)的非肝硬化患者进行活检。仅在组织学正常化(组织学活动指数[HAI]≤3)的患者中停用免疫抑制治疗,且至少随访 12 个月。
共有 17 名生化缓解至少 2 年的患者入组。5 名患者持续存在组织学炎症活动(HAI>3),不能停药。这些患者的 ALT(25 比 16 U/L;p=0.01)和 AST(26 比 22 U/L;p=0.01)值高于组织学缓解的患者。12 名患者停用免疫抑制药物;8 名(67%,置信区间 40-93%,p=0.4)在中位随访 62 个月(范围:13-75 个月)期间保持缓解;4 名(33%,置信区间 7-60%,p=0.4)在 1、6、11 和 40 个月后需要重新开始治疗,所有患者均无疾病进展或肝失代偿的临床迹象。未发现复发的预测因素。
在至少 2 年生化缓解后组织学正常化的患者中,有三分之二能够实现无治疗缓解。尽管患者人数较少,结果应谨慎解释,但这些发现支持在停药前进行肝活检。